VirtualScopics, LLC Commences Trading Today In The Public Markets

ROCHESTER, N.Y., Nov. 7 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , today announced the closing of a private placement totaling approximately $4.1 million and the simultaneous stock-for-stock merger with ConsultAmerica, Inc. The combined Company will operate under the name VirtualScopics, Inc. and will assume and execute VirtualScopics' medical image analysis business plan as its sole business. VirtualScopics will retain senior management and its current board of directors led by Warren Bagatelle of Loeb Partners. Shares will be listed on the Over-the-Counter (OTC) Bulletin Board initially under the trading symbol VSCP.OB. The Company plans to apply for listing its shares on the Nasdaq Small Cap Market as soon as practical. Following the closing of the private placement and merger, VirtualScopics has 23, 522, 871 shares of common stock [outstanding, including its Series A convertible preferred stock].

"The listing of our stock in the public markets represents the completion of several steps we have taken to financially position the Company for future growth," said Mr. Robert Klimasewski, president and CEO of the Company. "Significant investments from Pfizer and GE Health Care in our private financings have given us access to both capital and strategic introductions that will significantly benefit the Company moving forward. Other large shareholders include the University of Rochester, affiliates of Loeb Partners Corporation and Trillium Holdings. The University of Rochester has also had a paramount impact since the Company's inception by providing the ideal environment for the technology's research and development to take place," Mr. Klimasewski continued. "The listing provides the proper venue for attaining a higher level of corporate visibility, and allows investors to better assess VirtualScopics' value in relation to its publicly-traded peers."

VirtualScopics, Inc. is a premier provider of image-based biomarker solutions to customers in the healthcare industry. The Company's patented processes enable clients to more efficiently determine the effectiveness of drugs and devices and provides more efficiency and accuracy in clinical trials.

Today's private placement and merger transaction will enable VirtualScopics to pursue the research and development of its technology as well as expand sales and marketing activities.

The securities sold by VirtualScopics in the private placement and the exchange offer have not been registered under the Securities Act of 1933, may not be sold in the United States absent registration pursuant to the Securities Act, and are subject to certain lock-up provisions. The Company expects to file a registration statement for these securities by May, 2006.

About VirtualScopics:

VirtualScopics, Inc. is a leading developer of image-related biomarkers as well as the premier provider of innovative imaging solutions utilizing biomarkers for pharmaceutical development. VirtualScopics utilizes its patented suite of image analysis algorithms to detect, measure and analyze specific biological structures from medical image data, such as computed tomography (CT) and magnetic resonance imaging (MRI) scans.

VirtualScopics' computer-assisted analysis technique provides superior precision and reproducibility, enabling faster and more reliable detection of disease progression or therapeutic benefit, accelerating the clinical trial process, and providing a basis for future diagnostic applications. The Company's proprietary software algorithms can process hundreds of separate medical images taken during an MRI or CT session into a single, anatomically accurate three-dimensional model, providing clinical researchers a previously unobtainable source of reproducible data including the characterization of minute changes over time. This visionary biomedical firm evolved from research initially undertaken at the University of Rochester Medical Center and School of Engineering. For more information about VirtualScopics, visit http://www.virtualscopics.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there by any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under securities laws of any such state.

Forward-Looking Statements:

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.

Corporate Contact: Media Contact: Mr. Robert G. Klimasewski Ms. Tracy Bagatelle-Black President & Chief Executive Officer Media Relations VirtualScopics, Inc. Bagatelle-Black Public Relations 350 Linden Oaks 22010 Jodi Place Rochester, NY 14625 Santa Clarita, CA 91350 (585) 249-6231 (661) 263-1842 bob_klimasewski@virtualscopics.comtracy@bagatelleblack.com

VirtualScopics, Inc.

CONTACT: Corporate Contact - Mr. Robert G. Klimasewski, President & ChiefExecutive Officer of VirtualScopics, Inc, +1-585-249-6231,bob_klimasewski@virtualscopics.com; or Media Contact - Ms. TracyBagatelle-Black, Media Relations of Bagatelle-Black Public Relations forVirtualScopics, Inc., +1-661-263-1842, tracy@bagatelleblack.com

MORE ON THIS TOPIC